MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity

Published:2015-04-13 Issue:4 Volume:35 Page:448-458
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Xue J,Chi Y,Chen Y,Huang S,Ye X,Niu J,Wang W,Pfeffer L M,Shao Z-m,Wu Z-H,Wu J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc201596.pdf

Reference50 articles.

1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M et al. Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med 2005; 353: 1784–1792.

2. Dieras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22: 4958–4965.

3. Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K et al. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clinical Oncol 2011; 41: 867–875.

4. Lawrence G, Crawford J, Sherman F . Evaluating neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2002; 20: 2906–2907.

5. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456–1466.

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical implications of serum miR-34a in breast cancer and its predictive value for the efficacy of neoadjuvant chemotherapy;American Journal of Translational Research;2024

2. Molecular Pathways in Breast Cancer Chemoresistance;Handbook of Oncobiology: From Basic to Clinical Sciences;2024

3. Resistance to Endocrine Therapy in Breast Cancer;Overcoming Breast Cancer Therapy Resistance;2024

4. FBXW7 in breast cancer: mechanism of action and therapeutic potential;Journal of Experimental & Clinical Cancer Research;2023-09-02

5. Circulating microRNA profiles in Wilms tumour (WT): A systematic review and meta-analysis of diagnostic test accuracy;Non-coding RNA Research;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3